Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463896 | 0.86 | KDM4E (0.74) | SIGMAR1KDM4EIGF1RALDH1A1HTT | |
| SCHEMBL4471613 | 0.86 | KDM4E (0.74) | SIGMAR1KDM4EIGF1RFAAHALDH1A1 | |
| SCHEMBL4474183 | 0.86 | KDM4E (0.74) | SIGMAR1KDM4EIGF1RFAAHALDH1A1 | |
| SCHEMBL4471401 | 0.86 | KDM4E (0.74) | SIGMAR1KDM4EIGF1RFAAHALDH1A1 | |
| SCHEMBL4478754 | 0.82 | KDM4E (1.00) | SIGMAR1KDM4EIGF1RHTTMEN1 | |
| SCHEMBL4465545 | 0.82 | KDM4E (1.00) | SIGMAR1KDM4EIGF1RHTTMEN1 | |
| SCHEMBL4468044 | 0.82 | KDM4E (1.00) | SIGMAR1KDM4EIGF1RHTTMEN1 | |
| SCHEMBL28186295 | 0.82 | SIGMAR1 (0.90) | SIGMAR1KDM4EFAAHALDH1A1HTT | |
| SCHEMBL20804357 | 0.82 | SIGMAR1 (0.90) | SIGMAR1KDM4EFAAHALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL4466480 | 0.81 | KDM4E (0.97) | SIGMAR1KDM4EIGF1RHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | disclosed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | AANAT, GAP43, TPH2 | SIGMAR1 805/4885KDM4E 2865/4885IGF1R 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.